Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3102 ARTÍCULOS , VIENDO DEL 1366 AL 1380

Clozapine for medication-related pathological gambling in Parkinson disease

Rotondo A, Bosco D, Plastino M, Consoli A, Bosco F.

Mov Disord. 2010 Sep 15;25(12):1994-5. doi: 10.1002/mds.23177.

Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease

Rascol O, Barone P, Hauser RA, Mizuno Y, Poewe W, Schapira AH, Salin L, Sohr M, Debieuvre C; Pramipexole Switch Study Group.

Mov Disord. 2010 Oct 30;25(14):2326-32. doi: 10.1002/mds.23262.

Comparing exercise in Parkinson's disease--the Berlin LSVT®BIG study

Ebersbach G, Ebersbach A, Edler D, Kaufhold O, Kusch M, Kupsch A, Wissel J.

Mov Disord. 2010 Sep 15;25(12):1902-8. doi: 10.1002/mds.23212.

Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease

Stocchi F, Zappia M, Dall'Armi V, Kulisevsky J, Lamberti P, Obeso JA; Melevodopa Plus Carbidopa Study Group.

Mov Disord. 2010 Sep 15;25(12):1881-7. doi: 10.1002/mds.23206.

Controlled trial on the effect of 10 days low-frequency repetitive transcranial magnetic stimulation (rTMS) on motor signs in Parkinson's disease

Arias P, Vivas J, Grieve KL, Cudeiro J.

Mov Disord. 2010 Sep 15;25(12):1830-8. doi: 10.1002/mds.23055.

Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease

Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators; Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, Goetz C.

Mov Disord. 2010 Sep 15;25(12):1801-8. doi: 10.1002/mds.23006.

Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease

Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W.

Mov Disord. 2010 Nov 15;25(15):2542-9. doi: 10.1002/mds.23317.

Low-protein and protein-redistribution diets for Parkinson's disease patients with motor fluctuations: a systematic review

Cereda E, Barichella M, Pedrolli C, Pezzoli G.

Mov Disord. 2010 Oct 15;25(13):2021-34. doi: 10.1002/mds.23226.

Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease

Perez Lloret S, Rascol O.

Expert Opin Pharmacother. 2010 Sep;11(13):2221-30. doi: 10.1517/14656566.2010.510515.

High Levels of Copper, Zinc, Iron and Magnesium, but not Calcium, in the Cerebrospinal Fluid of Patients with Fahr's Disease

Hozumi I, Kohmura A, Kimura A, Hasegawa T, Honda A, Hayashi Y, Hashimoto K, Yamada M, Sakurai T, Tanaka Y, Satoh M, Inuzuka T.

Case Rep Neurol. 2010 May 7;2(2):46-51. doi: 10.1159/000313920.

[Deep brain stimulation--the newest physical method of treatment of depression]

Zyss T, Zieba A, Hese RT, Dudek D, Grabski B.

Psychiatr Pol. 2010 May-Jun;44(3):301-17.

Current and future indications for deep brain stimulation in pediatric populations

Lipsman N, Ellis M, Lozano AM.

Neurosurg Focus. 2010 Aug;29(2):E2. doi: 10.3171/2010.5.FOCUS1095.

The neuroprotective effect of talipexole from paraquat-induced cell death in dopaminergic neuronal cells

Gómez-Sánchez R, Bravo-San Pedro JM, Niso-Santano M, Soler G, Fuentes JM, González-Polo RA.

Neurotoxicology. 2010 Dec;31(6):701-8. doi: 10.1016/j.neuro.2010.07.005. Epub 2010 Jul 29.

Dopaminergic modulation of the default mode network in Parkinson's disease

Delaveau P, Salgado-Pineda P, Fossati P, Witjas T, Azulay JP, Blin O.

Eur Neuropsychopharmacol. 2010 Nov;20(11):784-92. doi: 10.1016/j.euroneuro.2010.07.001. Epub 2010 Jul 31.

Double-blind, randomized, placebo controlled trial on the effect of 10 days low-frequency rTMS over the vertex on sleep in Parkinson's disease

Arias P, Vivas J, Grieve KL, Cudeiro J.

Sleep Med. 2010 Sep;11(8):759-65. doi: 10.1016/j.sleep.2010.05.003. Epub 2010 Jul 31.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias